- Home
- RDI vs AKTX Comparison
RDI vs AKTX Comparison
Compare RDI & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- AKTX
- Stock Information
- Founded
- RDI 1937
- AKTX N/A
- Country
- RDI United States
- AKTX United States
- Employees
- RDI N/A
- AKTX N/A
- Industry
- RDI Movies/Entertainment
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- AKTX Health Care
- Exchange
- RDI Nasdaq
- AKTX Nasdaq
- Market Cap
- RDI 35.7M
- AKTX 35.7M
- IPO Year
- RDI N/A
- AKTX N/A
- Fundamental
- Price
- RDI $1.53
- AKTX $0.89
- Analyst Decision
- RDI
- AKTX Strong Buy
- Analyst Count
- RDI 0
- AKTX 2
- Target Price
- RDI N/A
- AKTX $3.30
- AVG Volume (30 Days)
- RDI 55.7K
- AKTX 256.6K
- Earning Date
- RDI 11-13-2025
- AKTX 08-13-2025
- Dividend Yield
- RDI N/A
- AKTX N/A
- EPS Growth
- RDI N/A
- AKTX N/A
- EPS
- RDI N/A
- AKTX N/A
- Revenue
- RDI $219,213,000.00
- AKTX N/A
- Revenue This Year
- RDI $5.21
- AKTX N/A
- Revenue Next Year
- RDI $11.45
- AKTX N/A
- P/E Ratio
- RDI N/A
- AKTX N/A
- Revenue Growth
- RDI 7.59
- AKTX N/A
- 52 Week Low
- RDI $1.17
- AKTX $0.57
- 52 Week High
- RDI $1.88
- AKTX $3.85
- Technical
- Relative Strength Index (RSI)
- RDI 56.79
- AKTX 53.12
- Support Level
- RDI $1.47
- AKTX $0.68
- Resistance Level
- RDI $1.60
- AKTX $0.89
- Average True Range (ATR)
- RDI 0.07
- AKTX 0.08
- MACD
- RDI -0.01
- AKTX 0.02
- Stochastic Oscillator
- RDI 42.86
- AKTX 98.50
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.